Public Storage
There’s more in store with these advertised prices.
Global Institute of Stem Cell Therapy and Research
In May 2020, a class-action lawsuit was filed against Global Institute of Stem Cell Therapy and Research for allegedly:
- Misleadingly representing that its stem cell therapy treatment can treat multiple diseases – including sickle cell anemia, leukemia, lymphoma, and thalassemia – when, according to the complaint, the treatment does not treat such diseases and is not approved by the FDA;
- Failing to disclose the risks associated with the treatment;
- Making false statements about one of the co-founder’s education, academic appointments, and clinical experience; and
- Falsely claiming that the defendants are affiliated with and have stem cell clinics set up at reputable medical institutions when, according to plaintiffs, they are not affiliated with and do not have clinics at the institutions.
Plaintiffs also claim that the defendants are not licensed to perform stem cell treatments in the United States. (Mendez et al v. Global Institute of Stem Cell Therapy and Research USA et al, Case No. 20-cv-915, S.D. Cal.)
The Latest
American Beverage Association’s Every Bottle Back Recycling Initiative
Inquiry finds trade group overstates environmental benefits of recycling program.
Hair-Raising Claims by Unilever’s Nutrafol Reported to Regulators
TINA.org files complaint with the FDA and FTC over company’s hair growth claims.
Consumer Alert: Hair Growth Products
Supplement and serum companies are targeting consumers experiencing hair loss.
CATrends: Marketing Claims for Products Containing PFAS
Class-action lawsuits target human and environmentally-friendly claims.